Navigation Links
Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
Date:6/3/2008

CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.

Watson has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the 40mg strength. Watson's marketing exclusivity will begin upon commercial launch. The Company plans to launch its Omeprazole Delayed-Release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and manufacturing of launch quantities. Watson plans to launch only the 40 mg strength.

Omeprazole is the generic equivalent to AstraZeneca's Prilosec(R) Delayed-Release Capsules USP and is indicated for the short-term treatment of active duodenal ulcer. For the 12-months ending March 2008, Prilosec(R) Delayed-Release Capsules and its generic equivalents had total U.S. sales of approximately $240 million, according to IMS Health.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, difficulties or delays in manufacturing; the difficulty of predicting the timing and outcome of litigation; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

Prilosec(R) is a registered trademark of the AstraZeneca group of companies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
2. Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
3. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
4. Watson to Present at the Bank of America 2008 Healthcare Conference
5. Texas Senator Kirk Watson Honored as Champion for Children by the AMERIGROUP Foundation
6. Watson Files Application for Generic SEASONIQUE(R)
7. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
8. Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find
9. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
10. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
11. Watson to Distribute Alendronate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate ... weather is too cold, dry or hot, water on the eye surface can evaporate, ... from the surrounding air. There’s only one problem, according to radio show and water ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From May ... Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s technology ... independent practice growth. , “It is our priority to see practices succeed in this ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Canadian author Mark Black is a ... Life From the Heart" around the world … with the help of his publisher Strategic ... 24, Mark Black lay in a hospital bed waiting for a miracle: He needed a ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis has resided ... testing areas, which now include pillows, sheets, mattress toppers, bed frames, and more. ...
(Date:5/6/2016)... Abilene, Texas (PRWEB) , ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer ... scientists and doctors, worldwide, what he has found in the Bible about helping to stop ... address it, and it is his hope that the health and science industries will pay ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Systemic Lupus Erythematosus Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Europe Systemic Lupus Erythematosus Market and Competitive ... into Systemic Lupus Erythematosus pipeline products, Systemic ...
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
Breaking Medicine Technology: